We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

4 hedge funds and large institutions have $1.56M invested in Moleculin Biotech in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.38% less ownership

Funds ownership: 5.6% → 3.23% (-2.4%)

13% less capital inflows, than outflows

Capital inflows: $211K | Capital outflows: $244K

43% less funds holding

Funds holding: 7 → 4 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
4
Holders Change
-3
Holders Change %
-42.86%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$211K

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Securities
Two Sigma Securities
New York
-$144K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$52K
3
Jane Street
Jane Street
New York
-$22K
4
Wedbush Securities
Wedbush Securities
California
-$19K
5
OneDigital Investment Advisors
OneDigital Investment Advisors
Kansas
-$5K

MBRX Hedge Fund Activity: Q3 2017 in Review

4 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2017, worth a combined $1.56M — down 20% from $1.95M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of MBRX and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Vanguard Group, adding an estimated $211K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $144K sold.

  • 4 institutional investors held Moleculin Biotech (MBRX) as of Q3 2017, down from 7 in Q2 2017.
  • Funds reported $1.56M of Moleculin Biotech stock for Q3 2017, down 20% quarter-over-quarter.
  • 0 funds opened new Moleculin Biotech positions in Q3 2017 and 2 closed out, a net change of -2 holders.
  • The largest Moleculin Biotech buyer in Q3 2017 was Vanguard Group, an estimated $211K added.
  • The largest Moleculin Biotech seller in Q3 2017 was Two Sigma Securities, an estimated $144K sold.

Based on aggregated 13F filings for Q3 2017.